IFNB1 and neoplasm: Indeed, the delayed tumor progression observed in IFNβ-vaccinated survivors re-challenged with wildtype tumors, whilst limited by the number of surviving mice available, draws us to speculate that IFNβ could similarly be a candidate to mediate the immune phenomenon of epitope spreading.